These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38296597)

  • 21. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
    Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.
    Wang Y; Li YR
    Curr Pharm Biotechnol; 2024; 25(15):2001-2011. PubMed ID: 38310449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.
    Boonchalermvichian C; Yan H; Gupta B; Rubin A; Baker J; Negrin RS
    Front Transplant; 2024; 3():1353803. PubMed ID: 38993780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.
    Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
    Jacoby E; Yang Y; Qin H; Chien CD; Kochenderfer JN; Fry TJ
    Blood; 2016 Mar; 127(10):1361-70. PubMed ID: 26660684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy.
    Han H; Wang L; Ding Y; Neuber B; Hückelhoven-Krauss A; Lin M; Yao H; Chen Q; Sauer T; Schubert ML; Guo Z; Müller-Tidow C; Schmitt M; Schmitt A
    Blood Adv; 2024 Jun; 8(11):2675-2690. PubMed ID: 38359409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
    Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
    Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. iNKT: A new avenue for CAR-based cancer immunotherapy.
    Liu Y; Wang G; Chai D; Dang Y; Zheng J; Li H
    Transl Oncol; 2022 Mar; 17():101342. PubMed ID: 35063813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
    Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.
    Mavers M; Maas-Bauer K; Negrin RS
    Front Immunol; 2017; 8():900. PubMed ID: 28824628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
    Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
    Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.